Generic Combination Products May Be Permitted Delivery Device Variations
Executive Summary
But US FDA officials say brand vs. generic product differences won't be appropriate in all cases and patient misuse remains a concern.
You may also be interested in...
FDA Eyes Adverse Events For Mylan's Wixela Inhub
As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.
Adverse Events For Generic Of GSK's Advair Diskus On US FDA’s Radar
As patients log device complaints for Mylan’s Advair Diskus generic Wixela Inhub, the agency is assessing whether additional reminders about the products’ differences are needed.
For Novartis' Generic Advair, Another 18 Months Was Too Far Into The Unknown
Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: